Current opinion in endocrinology, diabetes, and obesity · 2010
MicroRNAs in atherosclerosis and lipoprotein metabolism.
СтатьяResearch Support, N.I.H., IntramuralОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Vickers Kasey C, Remaley Alan T
Аннотация
PURPOSE OF REVIEW: MicroRNAs (miRNA) are mediators of post-transcriptional gene expression that likely regulate most biological pathways and networks. The study of miRNAs is a rapidly emerging field; recent findings have revealed a significant role for miRNAs in atherosclerosis and lipoprotein metabolism, which will be described in this review.
RECENT FINDINGS: The discovery of miRNA gene regulatory mechanisms contributing to endothelial integrity, macrophage inflammatory response to atherogenic lipids, vascular smooth muscle-cell proliferation, and cholesterol synthesis are described. Furthermore, recent evidence suggests that miRNAs may play a role in mediating the beneficial pleiotropic effects observed with statin-based lipid-lowering therapies. New modifications to miRNA mimetics and inhibitors, increasing targeting efficacy and cellular uptake, will likely enable future therapies to exploit miRNA gene regulatory networks.
SUMMARY: At this time, the applicability and full potential of miRNAs in clinical practice is unknown. Nonetheless, recent advances in miRNA delivery and inhibition hold great promise of a tremendous clinical impact in atherosclerosis and cholesterol regulation.
RECENT FINDINGS: The discovery of miRNA gene regulatory mechanisms contributing to endothelial integrity, macrophage inflammatory response to atherogenic lipids, vascular smooth muscle-cell proliferation, and cholesterol synthesis are described. Furthermore, recent evidence suggests that miRNAs may play a role in mediating the beneficial pleiotropic effects observed with statin-based lipid-lowering therapies. New modifications to miRNA mimetics and inhibitors, increasing targeting efficacy and cellular uptake, will likely enable future therapies to exploit miRNA gene regulatory networks.
SUMMARY: At this time, the applicability and full potential of miRNAs in clinical practice is unknown. Nonetheless, recent advances in miRNA delivery and inhibition hold great promise of a tremendous clinical impact in atherosclerosis and cholesterol regulation.